NCT05344573 Optimizing Pulsatility During Cardiopulmonary Bypass
| NCT ID | NCT05344573 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Colorado, Denver |
| Condition | Endothelial Dysfunction |
| Study Type | OBSERVATIONAL |
| Enrollment | 66 participants |
| Start Date | 2022-07-05 |
| Primary Completion | 2024-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 66 participants in total. It began in 2022-07-05 with a primary completion date of 2024-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cardiopulmonary bypass during cardiac surgery provides blood flow to the body during surgery but has adverse effects on different organs. Blood flow during cardiopulmonary bypass may be pulsatile or non-pulsatile, which may impact normal organ function after surgery. The study will collect data on the type of cardiopulmonary bypass used during surgery and organ function to determine if there is an association between the type of bypass and organ function.
Eligibility Criteria
Inclusion Criteria: * Age 50 to 70 * Able to provide informed consent * Scheduled for elective cardiac surgery with cardiopulmonary bypass Exclusion Criteria: * Patients undergoing emergency procedures * Diagnosed with sepsis * Experiencing delirium * Experiencing hemodynamic instability (heart rate \> 100 and systolic blood pressure \< 90) * Patients with a mechanical circulatory support device * Requiring vasoactive medications before surgery * Patients with a reduced left ventricular ejection fraction (less than 50%) * Patients with a contraindication to transesophageal echocardiography
Contact & Investigator
Nathan J Clendenen, MD, MS
PRINCIPAL INVESTIGATOR
University of Colorado Denver | Anschutz
Frequently Asked Questions
Who can join the NCT05344573 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 70 Years, studying Endothelial Dysfunction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05344573 currently recruiting?
Yes, NCT05344573 is actively recruiting participants. Contact the research team at nathan.clendenen@cuanschutz.edu for enrollment information.
Where is the NCT05344573 trial being conducted?
This trial is being conducted at Aurora, United States.
Who is sponsoring the NCT05344573 clinical trial?
NCT05344573 is sponsored by University of Colorado, Denver. The principal investigator is Nathan J Clendenen, MD, MS at University of Colorado Denver | Anschutz. The trial plans to enroll 66 participants.